Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Minerva NeurosciencesRockwell MedicalCatalyst BiosciencesProcessa PharmaceuticalsGalectin Therapeutics
SymbolNASDAQ:NERVNASDAQ:RMTINASDAQ:CBIONASDAQ:PCSANASDAQ:GALT
Price Information
Current Price$2.43$1.00$5.00$9.36$2.36
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.31.51.21.4
Analysis Score3.33.53.50.03.5
Community Score2.82.42.65.02.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.80.80.8
Earnings & Valuation Score0.00.60.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$6.75$5.50$17.00N/A$12.00
% Upside from Price Target177.78% upside450.00% upside240.00% upsideN/A408.47% upside
Trade Information
Market Cap$103.81 million$93.59 million$156.66 million$145.29 million$134.89 million
Beta1.491.112.07-0.062.04
Average Volume607,8032,049,297472,22875,3371,496,147
Sales & Book Value
Annual RevenueN/A$61.30 million$10,000.00N/AN/A
Price / SalesN/A1.5315,665.50N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.71 per share$0.32 per share$5.68 per share$1.46 per share$0.76 per share
Price / BookN/A3.130.88N/AN/A
Profitability
Net Income$-72,180,000.00$-34,130,000.00$-55,180,000.00$-3,360,000.00$-13,290,000.00
EPS($1.85)($0.56)($4.60)N/A($0.39)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-47.23%N/AN/AN/A
Return on Equity (ROE)-51.19%-117.67%-55.23%-79.69%-56.13%
Return on Assets (ROA)-29.75%-46.33%-45.82%-53.85%-49.42%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.50%N/A0.01%N/A
Current Ratio6.49%6.13%6.42%0.14%13.62%
Quick Ratio6.49%5.83%6.42%0.14%13.62%
Ownership Information
Institutional Ownership Percentage66.28%26.72%63.81%N/A17.58%
Insider Ownership Percentage12.00%4.70%4.00%54.60%40.70%
Miscellaneous
Employees1130034146
Shares Outstanding42.72 million93.59 million31.33 million15.52 million57.16 million
Next Earnings Date5/3/2021 (Estimated)5/10/2021 (Estimated)5/10/2021 (Estimated)5/21/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Whats Going On With GALT Stock And TV Stock Today?What's Going On With GALT Stock And TV Stock Today?
benzinga.com - April 14 at 3:58 PM
Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor ResponseGalectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response
finance.yahoo.com - April 14 at 3:58 PM
Galectin Gains on Product NewsGalectin Gains on Product News
baystreet.ca - April 14 at 10:58 AM
Galectin Therapeutics (GALT) Stock Climbs On Data PublicationGalectin Therapeutics (GALT) Stock Climbs On Data Publication
cnafinance.com - April 14 at 10:58 AM
Journal for ImmunoTherapy of Cancer Publishes...Journal for ImmunoTherapy of Cancer Publishes...
benzinga.com - April 14 at 12:56 AM
Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin,Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin,
apnews.com - April 14 at 12:56 AM
Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 TherapyJournal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
finance.yahoo.com - April 13 at 7:55 PM
-$0.17 EPS Expected for Galectin Therapeutics Inc. (NASDAQ:GALT) This Quarter-$0.17 EPS Expected for Galectin Therapeutics Inc. (NASDAQ:GALT) This Quarter
americanbankingnews.com - April 8 at 4:22 AM
Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians ...Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians ...
apnews.com - April 7 at 1:00 AM
Investors Buy High Volume of Galectin Therapeutics Call Options (NASDAQ:GALT)Investors Buy High Volume of Galectin Therapeutics Call Options (NASDAQ:GALT)
americanbankingnews.com - April 7 at 12:38 AM
Insider Buying: Galectin Therapeutics Inc. (NASDAQ:GALT) Director Buys 5,000 Shares of StockInsider Buying: Galectin Therapeutics Inc. (NASDAQ:GALT) Director Buys 5,000 Shares of Stock
americanbankingnews.com - April 6 at 10:42 AM
Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis StudyGalectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study
finance.yahoo.com - April 6 at 9:28 AM
Fund L.P. 10X Sells 10,000 Shares of Galectin Therapeutics, Inc. (NASDAQ:GALT) StockFund L.P. 10X Sells 10,000 Shares of Galectin Therapeutics, Inc. (NASDAQ:GALT) Stock
americanbankingnews.com - April 5 at 5:18 PM
Galectin Therapeutics (NASDAQ:GALT) Announces Quarterly  Earnings ResultsGalectin Therapeutics (NASDAQ:GALT) Announces Quarterly Earnings Results
americanbankingnews.com - April 1 at 6:48 PM
Galectin Therapeutics (NASDAQ:GALT) Releases Quarterly  Earnings Results, Beats Expectations By $0.03 EPSGalectin Therapeutics (NASDAQ:GALT) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
americanbankingnews.com - April 1 at 8:34 AM
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business UpdateGalectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 31 at 1:01 PM
 Analysts Anticipate Galectin Therapeutics, Inc. (NASDAQ:GALT) Will Announce Earnings of -$0.16 Per Share Analysts Anticipate Galectin Therapeutics, Inc. (NASDAQ:GALT) Will Announce Earnings of -$0.16 Per Share
americanbankingnews.com - March 22 at 12:14 AM
OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 TherapyOncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy
finance.yahoo.com - March 8 at 11:34 AM
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences ConferenceGalectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 4 at 12:28 PM
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences ConferenceGalectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 4 at 12:28 PM
What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)?What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)?
finance.yahoo.com - January 31 at 9:00 AM
Insider Sells Galectin Therapeutics StockInsider Sells Galectin Therapeutics Stock
finance.yahoo.com - January 19 at 6:00 PM
GALT Jan 2021 10.000 putGALT Jan 2021 10.000 put
uk.finance.yahoo.com - January 1 at 11:21 PM
Galectin Therapeutics Inc. Common Stock (GALT)Galectin Therapeutics Inc. Common Stock (GALT)
nasdaq.com - December 18 at 9:18 PM
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
finance.yahoo.com - December 11 at 8:19 AM
DateCompanyBrokerageAction
9/11/2020Minerva NeurosciencesWilliam BlairReiterated Rating
7/2/2020Minerva NeurosciencesHC WainwrightReiterated Rating
7/1/2020Minerva NeurosciencesJMP SecuritiesReiterated Rating
6/1/2020Minerva NeurosciencesBTIG ResearchLower Price Target
5/29/2020Minerva NeurosciencesJefferies Financial GroupDowngrade
12/2/2019Minerva NeurosciencesChardan CapitalReiterated Rating
8/3/2018Minerva NeurosciencesCitigroupBoost Price Target
11/11/2019Rockwell MedicalPiper Jaffray CompaniesLower Price Target
6/24/2019Rockwell MedicalCantor FitzgeraldInitiated Coverage
6/19/2019Rockwell MedicalIfs SecuritiesDowngrade
3/4/2021Catalyst BiosciencesRaymond JamesSet Price Target
2/10/2021Catalyst BiosciencesPiper SandlerInitiated Coverage
11/5/2020Catalyst BiosciencesLifesci CapitalReiterated Rating
8/6/2020Catalyst BiosciencesCi CapitalReiterated Rating
1/4/2019Catalyst BiosciencesCIBCInitiated Coverage
1/4/2019Catalyst BiosciencesOppenheimerInitiated Coverage
6/21/2018Catalyst BiosciencesB. RileyDowngrade
12/8/2020Processa PharmaceuticalsBenchmarkInitiated Coverage
10/28/2020Processa PharmaceuticalsCraig HallumInitiated Coverage
(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.